原題
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.

Journal: Ann Oncol (CiteScore 2022: 63)
DOI: 10.1016/j.annonc.2026.05.693
PMID: 42167437